Adbry® for moderate-to-severe atopic dermatitis

Strongly recommended by AAD and AAAAI guidelines as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients^1,2

Rapid itch
data³

SEE ITCH DATA

Long-term efficacy data

(16 and 52 weeks)^4,5

SEE EFFICACY DATA

True flexible
dosing^6*†

VIEW DOSING

6 years and
counting of
safety data^3,5,7

SEE SAFETY DATA

*Initial loading dose for adults is 2 x 300-mg autoinjectors or 4 x 150-mg prefilled 1 mL syringes. Maintenance dose is q2w or q4w.⁶

^†q4w for adult patients <220 lbs who achieve clear or almost clear skin after 16 weeks.

INDICATION

ADBRY^® (tralokinumab-Idrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

ADBRY is contraindicated in patients who have known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis and angioedema have occurred after administration of ADBRY. If a serious hypersensitivity reaction occurs, discontinue ADBRY immediately and initiate appropriate therapy.
Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received ADBRY. Conjunctivitis was the most frequently reported eye disorder. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.
Parasitic (Helminth) Infections: Treat patients with pre-existing helminth infections before initiating treatment with ADBRY. If patients become infected while receiving ADBRY and do not respond to antihelminth treatment, discontinue treatment with ADBRY until the infection resolves.
Risk of Infection with Live Vaccines: ADBRY may alter a patient’s immunity and increase the risk of infection following administration of live vaccines. Prior to initiating therapy with ADBRY, complete all age appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines during treatment with ADBRY. Limited data are available regarding coadministration of ADBRY with non-live vaccines.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥1%) are upper respiratory infections, conjunctivitis, injection site reactions, and eosinophilia.

USE IN SPECIFIC POPULATIONS

Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADBRY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/. There are limited data from the use of ADBRY in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, ADBRY may be transmitted from the mother to the developing fetus.
Lactation: There are no data on the presence of tralokinumab-ldrm in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is present in breast milk. The effects of local gastrointestinal exposure and limited systemic exposure to ADBRY on the breastfed infant are unknown.
Pediatric Use: Safety and effectiveness of ADBRY have not been established in pediatric patients younger than 12 years of age.

References:

1. Davis DMR, et al. J Am Acad Dermatol. 2024:90(2):e43-e56. doi:10.1016/j.jaad.2023.08.102. 2. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, et al. Ann Allergy Asthma Immunol. 2024;132(3):274-312. doi:10.1016/j.anai.2023.11.009. 3. Data on file. LEO Pharma Inc. 4. Blauvelt A, et al. Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control. Poster presented at: 32nd annual Congress of the European Academy of Dermatology and Venereology (EADV): October 11-14, 2023; Berlin, Germany. 5. Blauvelt A, et al. Long-term safety and efficacy of tralokinumab in adults and adolescents with moderate-to-severe atopic dermatitis treated for up to 6 years. Poster presented at: 44th Annual Fall Clinical Dermatology Congress: October 24-27, 2024; Las Vegas, NV. 6. ADBRY. Prescribing information. LEO Pharma Inc. 7. Reich K, et al. Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials. Poster presented at: Revolutionizing Atopic Dermatitis (RAD) Conference; April 29-May 1, 2023; Washington, DC.

Start Fast.
Stay Powerful.

Keep their AD in check for what lies ahead.

Rapid itch
data³

Long-term efficacy data

True flexible
dosing^6*†

6 years and
counting of
safety data^3,5,7

INDICATION

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

References:

You are about to leave AdbryHCP.com.

You are leaving the AdbryHCP.com site to access the Digital Enrollment Form

You are leaving the AdbryHCP.com site to access the HCP eRx Program Certification Form

Start Fast. Stay Powerful.

Keep their AD in check for what lies ahead.

Rapid itch data3

Long-term efficacy data

True flexible dosing6*†

6 years and counting of safety data3,5,7

INDICATION

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

References:

Start Fast.
Stay Powerful.

Rapid itch
data³

True flexible
dosing^6*†

6 years and
counting of
safety data^3,5,7